AMMF > FIGHT-302

Cholangiocarcinoma

FIGHT-302

FIGHT-302 is a multi-centre international study to evaluate the efficacy and safety of pemigatinib versus chemotherapy in unresectable or metastatic cholangiocarcinoma.

This study will compare chemotherapy (CisGem) with an FGFR-inhibitor in FGFR-altered patients and will require prior analysis of a tumour biopsy to determine that there is the appropriate FGFR-alteration.

Full Title: FIGHT-302: A Phase 3 Study of First-line Pemigatinib Versus Gemcitabine Plus Cisplatin for Cholangiocarcinoma With FGFR2 Fusions or Rearrangements.

This study is open and recruiting at the following UK locations:

  • Aberdeen Royal Infirmary – Dr Ishtiag Zubairi
  • Addenbrookes Hospital, Cambridge – Dr Bristi Basu
  • The Royal Marsden, London – Dr Naureen Starling
  • Hammersmith Hospital, London (Imperial College) – Dr Harpreet Wassan
  • University College Hospital, London – Professor John Bridgewater
  • Maidstone Hospital – Dr Justin Waters
  • The Christie, Manchester – Dr Mairead McNamara
  • University Hospital, Coventry – Dr Martin Scott Brown
  • Velindre Cancer Centre, Cardiff – Dr Kein Yim

and at

  • St Vincent’s University Hospital, Dublin, Ireland – Professor Raymond McDermott

More details of the study, and European locations currently recruiting, can be found here:
https://clinicaltrials.gov/ct2/show/NCT03656536

Also, see:
https://bepartofresearch.nihr.ac.uk/ and search for Study: FIGHT-302

Incyte:  https://www.incyte.com

Back to previous page